Does Blue Cross Blue Shield of Michigan Cover Ozempic?

How BCBSM Formularies Work for Ozempic

BCBSM places Ozempic on its commercial drug formulary as a non-preferred brand, usually Tier 3 or Tier 4 depending on which product your employer or exchange plan selected. That tier placement determines your cost-share after a deductible is met.

The 2024 Novo Nordisk prescribing label lists Ozempic as indicated for adults with type 2 diabetes to improve glycemic control and, at the 1 mg dose, to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The FDA approved that cardiovascular indication based on the SUSTAIN-6 trial (N=3,297), in which 6.6% of semaglutide-treated patients experienced a cardiovascular event vs. 8.9% on placebo over 104 weeks. That dual indication matters because it gives prescribers two distinct clinical arguments to cite during prior authorization.

Most BCBSM commercial plan documents distinguish between "preferred brand" drugs (Tier 3) and "non-preferred brand" drugs (Tier 4). On a typical Tier 3 plan, members pay 30-40% coinsurance. On Tier 4, that coinsurance can reach 50% before out-of-pocket maximums apply. BCBSM's Blue Preferred PPO plans and BCN HMO plans each maintain their own formulary, so the tier for Ozempic on your specific Blue plan may differ from a colleague's plan even within the same employer group.

The simplest way to confirm your tier is to log into the BCBSM member portal at bcbsm.com and run the drug cost estimator with your plan ID. Alternatively, your pharmacist can run a test claim before you fill the prescription to get an exact copay figure.

What Prior Authorization Criteria Does BCBSM Typically Require?

Prior authorization for Ozempic under BCBSM commercial plans usually requires documentation of a confirmed type 2 diabetes diagnosis, at least one prior trial of metformin (unless contraindicated), and an HbA1c above a threshold that commonly ranges from 7.0% to 8.0%.

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend adding a GLP-1 receptor agonist when metformin alone does not achieve glycemic targets, particularly when the patient also has established cardiovascular disease, heart failure, or chronic kidney disease. BCBSM clinical coverage policies frequently mirror ADA guidance, so having an HbA1c above 7.0% on metformin monotherapy is typically the minimum bar for approval.

Step therapy is the rule, not the exception. BCBSM prior authorization forms for semaglutide commonly require:

1. A diagnosis of type 2 diabetes (ICD-10 E11.x)
2. Documentation of metformin use for at least 90 days (or a documented contraindication such as eGFR <30 mL/min/1.73m² or lactic acidosis history)
3. HbA1c above the plan's threshold, usually 7.5% or 8.0%, on current therapy
4. In some plans, a failed trial of a sulfonylurea or SGLT2 inhibitor

Your prescriber should submit the PA through CoverMyMeds or the BCBSM provider portal. Turnaround on standard PA requests is typically 3-5 business days; urgent requests must be processed within 24-72 hours under Michigan insurance regulations.

Does BCBSM Cover Ozempic for Weight Loss?

No, not on standard commercial plans. Ozempic is FDA-approved for type 2 diabetes, not obesity. Wegovy (semaglutide 2.4 mg) is the FDA-approved version for chronic weight management. The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo. Despite that compelling efficacy data, most standard BCBSM commercial plans exclude weight-loss drugs by default.

Some employer groups in Michigan specifically purchase an obesity management rider that adds Wegovy or other anti-obesity medications to the formulary. If your employer has added that rider, you may have coverage for Wegovy with a separate prior authorization that focuses on BMI (typically BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia) per FDA labeling criteria for Wegovy.

Prescribing Ozempic off-label for weight loss in a patient without diabetes and billing it as a diabetes drug is not appropriate and will result in PA denial. If your primary goal is weight management without a type 2 diabetes diagnosis, the correct path is pursuing Wegovy coverage through an obesity benefit, or discussing compounded semaglutide or alternative GLP-1 agents with a physician who understands your plan's specific provisions.

Medicare and Medicaid Considerations in Michigan

Medicare Part D plans cover Ozempic for type 2 diabetes because it carries an FDA-approved non-weight-loss indication. However, the Medicare Modernization Act of 2003 explicitly excludes drugs used for weight loss from Part D coverage, which means Wegovy remains uncovered under most Medicare Part D plans. Ozempic prescribed for its diabetes indication does not trigger that exclusion.

Michigan Medicaid (Healthy Michigan Plan) covers semaglutide for type 2 diabetes through the Medicaid fee-for-service formulary, but managed care organizations (MCOs) like Molina Healthcare of Michigan, Priority Health, and McLaren Health Plan administer their own formularies. Each MCO may have distinct PA criteria. Michigan Medicaid typically classifies Ozempic as a preferred or non-preferred drug depending on the MCO, and step therapy through metformin remains standard.

For Medicare Advantage plans sold by BCBSM (branded as Blue Cross Medicare Advantage), the Part D drug benefit follows CMS rules. That means Ozempic for type 2 diabetes is generally covered, subject to tier and PA requirements that CMS requires insurers to post in the Annual Notice of Change each October.

How to Get Prior Authorization Approved: A Practical Framework

Getting a BCBSM prior authorization approved for Ozempic is more predictable when the prescriber packages the clinical record deliberately. The following framework reflects the documentation structure that tends to result in first-pass approvals based on what PA specialists and endocrinologists report in clinical practice.

Step 1. Anchor the diagnosis clearly. The PA form must list ICD-10 E11.x (type 2 diabetes) as the primary indication. Including a secondary cardiovascular disease code (I25.x for coronary artery disease, or N18.x for CKD) strengthens the case by invoking the SUSTAIN-6 cardiovascular outcome data, which BCBSM clinical reviewers recognize.

Step 2. Document prior therapy failures specifically. "Patient tried metformin" is weaker than "Patient took metformin 2 to 000 mg daily for 6 months; HbA1c remained 8.3% (lab date: 09/15/2024)." Dates and lab values move the reviewer away from subjective judgment.

Step 3. Cite a contraindication if step therapy cannot be completed. An eGFR <30 mL/min/1.73m² documented in the chart is a recognized contraindication to metformin per FDA labeling. Severe GI intolerance with documented clinic visits also qualifies. Reference the specific lab or visit note by date.

Step 4. Include the cardiovascular or renal outcome argument when applicable. The 2023 ADA/EASD consensus report on type 2 diabetes management states: "In patients with T2D and established CVD or high CVD risk, CKD, or HF, a GLP-1 RA or SGLT2 inhibitor with proven CV or renal benefit is recommended independent of HbA1c." Quoting that directly in the PA letter gives the reviewer a guideline anchor to approve without escalating to a physician-to-physician review.

Step 5. Request an expedited review if the patient has active cardiovascular disease. BCBSM and Michigan state regulations require insurers to issue expedited PA decisions within 72 hours when a standard review timeline could seriously jeopardize the member's health.

Step 6. Appeal with a prescriber letter if denied. Include the specific denial reason from the Explanation of Coverage, lab values, a summary of prior therapies, and the relevant ADA guideline language. First-level appeals that include quantitative HbA1c trend data (e.g., HbA1c rising from 7.2% to 8.5% over 12 months) tend to be more successful than those relying on narrative alone.

What Ozempic Actually Costs Through BCBSM vs. Without Insurance

The wholesale acquisition cost of Ozempic as of early 2025 is approximately $935 per 28-day supply for the 1 mg dose. Through a BCBSM Tier 3 plan with 30% coinsurance and a $1,500 annual deductible, a patient who has met their deductible might pay roughly $280-$375 per month. On a Tier 4 plan at 50% coinsurance post-deductible, that figure climbs to approximately $465.

Novo Nordisk's Ozempic savings card reduces out-of-pocket cost to as low as $25 per month for eligible commercially insured patients (those with commercial or private insurance, not Medicare or Medicaid). The savings card cannot be used alongside federal or state government insurance programs. Eligibility and terms are maintained on Novo Nordisk's patient assistance page.

For uninsured patients or those whose plans exclude Ozempic entirely, Novo Nordisk's Patient Assistance Program (NovoCare) provides free medication to qualifying low-income patients. Income thresholds and application instructions change annually; patients should apply directly through NovoCare rather than through third-party sites.

GoodRx and similar discount programs can reduce Ozempic's cash price to approximately $850-$900 at most Michigan pharmacies, which is marginally lower than list price but still substantially more than using insurance coverage or a manufacturer's savings card.

What Happens If BCBSM Denies Coverage?

A denial is not the end of the road. Michigan's Insurance Code requires BCBSM to provide a written explanation for any adverse benefit determination. That letter will specify whether the denial is based on medical necessity, step therapy, or formulary exclusion. Each denial type has a specific appeal pathway.

For step therapy denials, Michigan Public Act 510 of 2018 (Michigan's Step Therapy Override Law) requires insurers to grant a step therapy override when the required drug is contraindicated, has been previously tried and failed, or when a clinical peer-reviewed study supports that the prescribed drug is medically necessary. Your prescriber should reference this statute directly in the appeal letter.

The FDA's guidance on drug approvals can be cited to document that Ozempic's cardiovascular outcome labeling makes it distinct from other GLP-1 agents. That distinction may justify skipping to Ozempic specifically rather than a cheaper GLP-1 such as dulaglutide (Trulicity) or liraglutide (Victoza), which BCBSM may prefer as step-therapy alternatives.

If the internal appeal fails, members can request an Independent Medical Review through the Michigan Department of Insurance and Financial Services (DIFS). External reviewers are bound by Michigan law to apply evidence-based clinical standards, not simply formulary preference.

Alternatives BCBSM May Cover More Easily

When Ozempic is denied or prohibitively expensive through BCBSM, several alternatives may be covered at a lower tier or with fewer PA hurdles.

Trulicity (dulaglutide) is a weekly GLP-1 injection that BCBSM often places on Tier 3 as a preferred GLP-1 agent. The REWIND trial (N=9,901) showed dulaglutide reduced the composite cardiovascular endpoint by 12% relative to placebo over a median 5.4 years in patients with type 2 diabetes. For patients who need GLP-1 therapy and a cardiovascular benefit, dulaglutide is a clinically defensible alternative if the prescriber and patient are open to it.

Victoza (liraglutide 1.2 mg or 1.8 mg) is a daily GLP-1 injection. It carries an FDA approval for cardiovascular risk reduction in adults with type 2 diabetes based on the LEADER trial (N=9,340), in which liraglutide reduced major adverse cardiovascular events by 13% vs. placebo over 3.5 years. BCBSM may place liraglutide on a lower tier than semaglutide in some plan years.

Metformin plus SGLT2 inhibitor combinations (empagliflozin, dapagliflozin) may satisfy step therapy requirements while providing cardiovascular and renal benefits, positioning the patient for a subsequent GLP-1 PA that documents failure to achieve glycemic targets.

Discussing these options with a prescriber who understands BCBSM's current formulary is the fastest way to find a covered path that still meets your clinical goals.

Key Documentation Your Prescriber Should Keep on File

Insurance audits and PA renewals are easier when the clinical chart contains dated records of: HbA1c values at each visit, prior medications with start and stop dates, documented adverse effects or contraindications, and notes linking the GLP-1 choice to a specific guideline recommendation. Annual PA renewals for Ozempic will require updated HbA1c values showing that the medication is producing a clinical benefit, typically a reduction of at least 0.5-1.0% from baseline.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy and the ADA's Standards of Care are the two documents most commonly cited by BCBSM clinical reviewers when evaluating GLP-1 PAs. Having those guideline references in the prescriber's letter is not a formality. Clinical reviewers at BCBSM are required to apply evidence-based criteria, and named guideline citations give them a defensible basis for approval.